GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

The FTSE 100 index has started the year well as it surged to a record high. It moved to a high of £8,645, up by over 75% from ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

With little fanfare, the Biden administration stacked a critical committee that helps set U.S. vaccination policy with new ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts. The ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...